Literature DB >> 15686463

Prediction of haemorrhage in the early stage of acute myeloid leukaemia by flow cytometric analysis of platelet function.

Eva Birgitte Leinoe1, Marianne Hutchings Hoffmann, Erik Kjaersgaard, Joern Dalsgaard Nielsen, Olav Jonas Bergmann, Tobias Wirenfeldt Klausen, Hans Erik Johnsen.   

Abstract

Haemorrhage is often responsible for the lethal course of acute myeloid leukaemia (AML). Previously, multiple platelet function defects were identified by flow cytometric analysis of platelet activation markers in AML. The role of flow cytometric analysis of platelet function in characterization of prognostic markers of haemorrhage in AML patients has not been well elucidated. The objective of this prospective study was to analyse platelet function in 50 AML patients at diagnosis and to compare results with clinical bleeding score, graded by common toxicity criteria. Platelet activation markers CD62P, CD42b, CD63 and PAC-1 were analysed following in vitro activation by thrombin receptor activating peptide. The following plasma haemostasis parameters were measured: soluble P-selectin, activated partial thromboplastin time, thrombin time, prothrombin time, D-dimer, fibrinogen, and von Willebrand factor antigen. In a multivariate analysis, P-selectin (CD62P) <36 molecules of equivalent soluble fluorochrome x 10(3) (P < 0.0015) and platelet count <40 x 10(9)/l (P = 0.01) were significant predictors of haemorrhage at diagnosis. Haemorrhage at diagnosis predicted grade 3-4 haemorrhage in the first 28 d following diagnosis (P = 0.018). The presented results indicate that low P-selectin is a prognostic marker of haemorrhage in AML.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15686463     DOI: 10.1111/j.1365-2141.2004.05335.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

1.  Impaired mitochondrial activity explains platelet dysfunction in thrombocytopenic cancer patients undergoing chemotherapy.

Authors:  Constance C F M J Baaten; Floor C J I Moenen; Yvonne M C Henskens; Frauke Swieringa; Rick J H Wetzels; René van Oerle; Harry F G Heijnen; Hugo Ten Cate; Graham P Holloway; Erik A M Beckers; Johan W M Heemskerk; Paola E J van der Meijden
Journal:  Haematologica       Date:  2018-06-07       Impact factor: 9.941

2.  Platelet function testing at low platelet counts: When can you trust your analysis?

Authors:  Niklas Boknäs; Ankit S Macwan; Anna L Södergren; Sofia Ramström
Journal:  Res Pract Thromb Haemost       Date:  2019-03-19

3.  Platelet Defects in Acute Myeloid Leukemia-Potential for Hemorrhagic Events.

Authors:  Horia Bumbea; Ana Maria Vladareanu; Ion Dumitru; Viola Maria Popov; Cristina Ciufu; Anca Nicolescu; Minodora Onisai; Cristina Marinescu; Diana Cisleanu; Irina Voican; Sinziana Sarghi
Journal:  J Clin Med       Date:  2021-12-26       Impact factor: 4.241

4.  Analysis of Risk Factors of Coagulation Dysfunction and Hemorrhage in Newly Diagnosed Hyperleukocytic Acute Myeloma Leukemia.

Authors:  Anjie Xu; Pan Liu; Fuling Zhou
Journal:  Contrast Media Mol Imaging       Date:  2022-07-13       Impact factor: 3.009

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.